1. Knowledge of databases for sequences and structures of
antibodies.
2. Using tools for
sequence analysis: applications to the study of
repertoires of antibody recognition sites and to the study of specificities
(autoimmune diseases, infectious diseases, AIDS, leukemias, lymphomas,
myelomas...).
3. Bioinformatic structural analysis for
the humanization of monoclonal antibodies for therapeutic purposes (IMGT
Collier de Perles methodology).
4. Prediction and analysis of
immunogenicity of therapeutic antibodies.
5. Structural analysis of antibody
fragments and their recognition sites for the discovery of new drugs.
This TU will be based in particular on the tools and databases developed by IMGT(r), the international ImMunoGeneTics information system (r), http://www.imgt.org, the international reference system used by many pharmaceutical companies (CentocorResearch and Development Inc. Johnson & Johnson USA, AMGEN Inc. USA, Sanofi-Aventis GmbH Germany, Merck & Co. Inc. USA, Chugai Pharmaceutical Co. Ltd. Japan, Astellas Pharma Inc. Japan, Agensys Inc. USA, Merck Serono SA Switzerland, F. HOFFMAN-LA ROCHE Switzerland, etc..).
The teaching requires a PC connected to Internet per student.Acquired Skills :
1. Methodological skills in immunoinformatics.
2. Bioinformatics skills in antibody engineering.
3. Skills in bioinformatic analysis of therapeutic antibodies.